Skip to content
Evigrade
MajorAntifungals, triazole derivatives×Antianginal – late sodium current inhibitor

Updated · Methodology

Mechanism

CYP3A4 is the main enzyme that metabolises ranolazine. Its inhibitors raise ranolazine levels and with them the risk of dose-related adverse reactions such as nausea and dizziness (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA). Fluconazole is a moderate CYP3A4 inhibitor, and its effect on the enzymes persists for 4–5 days after fluconazole is stopped (fluconazole SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The documents do not say how much fluconazole raises ranolazine levels. For comparison, diltiazem, another moderate CYP3A4 inhibitor, raised them 1.5- to 2.4-fold (EMA). Both drugs prolong the QT interval. Ranolazine blocks the IKr potassium current in a dose-dependent way (EMA). Fluconazole also inhibits IKr and, by inhibiting CYP3A4, may amplify QT prolongation caused by other drugs (AEMPS).

Symptoms

Higher ranolazine levels make dizziness, nausea and vomiting more likely. In an intravenous overdose study in healthy volunteers, double vision, lethargy and fainting were also seen (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA). QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). Warning signs of a possible arrhythmia are feeling faint or lightheaded and an irregular or fast heartbeat (ranolazine label, US Food and Drug Administration, FDA). QT prolongation and torsade de pointes have been reported very rarely with fluconazole, and these cases included seriously ill patients with structural heart changes, electrolyte abnormalities or other medicines. Low potassium and advanced heart failure raise the risk of life-threatening ventricular arrhythmias (fluconazole SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).

Management

Limit the ranolazine dose. The US label allows no more than 500 mg of ranolazine twice daily with moderate CYP3A inhibitors and names fluconazole among them (ranolazine label, US Food and Drug Administration, FDA). The European ranolazine summary of product characteristics (SmPC) also lists fluconazole as a moderate CYP3A4 inhibitor: adjust the ranolazine dose carefully and reduce it if needed (ranolazine SmPC, European Medicines Agency, EMA). If dizziness, nausea or vomiting appear, reduce ranolazine to 500 mg or 375 mg twice daily, and stop it if the symptoms do not resolve. When several factors that raise ranolazine exposure are combined, monitor frequently for adverse reactions (EMA). The Spanish fluconazole SmPC contraindicates fluconazole with drugs that prolong the QT interval and are metabolised by CYP3A4 and names cisapride, astemizole, pimozide, quinidine and erythromycin. Ranolazine is not on this list, although its own documents state that it has both properties (fluconazole SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; EMA). The same SmPC lists halofantrine, which has the same properties, among combinations that are not recommended, and both ranolazine documents give a dose rule for fluconazole rather than a contraindication (AEMPS; EMA; FDA). Use ranolazine with caution with other drugs that affect the heart-rate-corrected QT interval (QTc), in congenital or familial long QT syndrome and in known acquired QT prolongation (EMA). Use fluconazole with caution in conditions that predispose to arrhythmia (AEMPS). The effect of fluconazole on the enzymes persists for 4–5 days after fluconazole is stopped (AEMPS), but the documents do not say when the previous ranolazine dose can be resumed.

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Fluconazole

Other interactions with Ranolazine